Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, and Crown CRO, a contract research organization based in Finland, today announced Crown’s engagement to manage Adial’s Phase 3 clinical trial for AD04 for the treatment of alcohol use disorder (AUD). The FDA approved protocol for this Phase 3 clinical trial is a 24-week trial with 290 patients in 30 clinical sites in 5 European countries.
It has been a privilege to operate in the clinical […]
Crown CRO is proud to be part of the CoroPrevention Clinical Trial – a unique opportunity to evaluate personalized prevention in CHD.
Coronary Heart Disease (CHD) affects both men and women and […]
I started working at Crown in September 2019, right after […]
An elderly lady sits in her small room in a […]
Unfortunately, this CRA Training Course has been canceled due to […]